Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis.
作者信息
Mukherjee Sudipto, Brown-Bickerstaff Cherrishe, Falkenstein Angelica, Makinde Adeola Y, Bland Emily, Laney JaLyna, Garretson Marné, Huggar David, McBride Ali
机构信息
Department of Hematology and Medical Oncology Taussig Cancer Institute, Cleveland Clinic Cleveland Ohio USA.
Formerly of Cardinal Health Dublin Ohio USA.
出版信息
Hemasphere. 2024 Jan 30;8(1):e38. doi: 10.1002/hem3.38. eCollection 2024 Jan.
DOI:10.1002/hem3.38
PMID:38434524
Abstract
摘要
相似文献
[1]
[2]
[4]
Novel agents for myelodysplastic syndromes.
J Oncol Pharm Pract. 2021-12
[5]
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med. 2020-1-9
[6]
[7]
Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
Future Oncol. 2021-4
[8]
[9]
Luspatercept in Myelodysplastic Syndromes: Who and When?
Hematol Oncol Clin North Am. 2020-4
[10]
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
CPT Pharmacometrics Syst Pharmacol. 2020-7
引用本文的文献
[1]
Advances and Challenges in the Management of Myelodysplastic Syndromes.
Cancers (Basel). 2025-7-25
[2]
本文引用的文献
[2]
[3]
The wider perspective: twenty years of clinical trials in myelodysplastic syndromes.
Br J Haematol. 2022-1
[4]
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med. 2020-1-9
[5]
Electronic health records to facilitate clinical research.
Clin Res Cardiol. 2017-1
[6]
[7]
[8]
[9]
Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations.
JACC Cardiovasc Interv. 2008-6
[10]
Management of anemia associated with myelodysplastic syndrome.
Semin Hematol. 2005-4
Zotero 插件